Stimulanzien in der Therapie einer ADHS sind schädlich für Wachstum und Knochendichte – Kontra

• Literatur

• 1 Banaschewski T, Bauer M, Bea M. et al. S3-Leitlinie Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. 2017. https://www.awmf.org/leitlinien/detail/ll/028-045.html
• 2 Swanson JM, Arnold LF, Molina BSG. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 2017; 58: 663-678
• 3 Richardson E, Seibert T, Uli NK. Growth perturbations from stimulant medications and inhaled corticosteroids. Transl Pediatr 2017; 17: 237-247
• 4 Bonthuis M, van Stralen KJ, Verrina E. et al. Use of national and international growth charts for studying height in European children: development of up-to-date European height-for-age charts. PLoS One 2012; 7 e42506
• 5 Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medication and diminished bone health in children and adolscents. J Pediatr Orthop 2017; 37: 348-354
• 6 Feuer AJ, Thai A, Demmer RT. et al. Association of stimulant medication use with bone mass in children and adolescents with attention-deficit/hyperactivity disorder. JAMA Pediatr 2016; 170: e162804
• 7 Tandon M, Tillman R, Agrawal A. et al. Trajectories of ADHD severity over 10 years from childhood into adulthood. Atten Defic Hyperact Disord 2016; 8: 121-130
• 8 Meinzer MC, Pettit JW, Waxmonsky JG. et al. Does Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) Predict Levels of Depressive Symptoms during Emerging Adulthood?. J Abnorm Child Psychol 2016; 44: 787-797